06/02/2017
Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
Zealand Pharma A/S (“Zealand”) announces that the last patient has been dosed in a phase II proof-of-concept, dose-finding trial with glepaglutide1 for the treatment of short bowel syndrome (SBS). SBS is a serious condition involving intestinal function [...]
